StockData
GENELUX Corp logo

GENELUX Corp (GNLX) company profile

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.00+0.08 (+4.17%)

Close on Nov 17, 2026Market cap $90.49MP/E –Yield –

About Genelux

Pharmaceutical Preparations, SIC 2834

Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies. The company designs off-the-shelf personalized treatments engineered to selectively destroy cancer cells and stimulate an immune response targeting unique tumor neoantigens. Its proprietary selection and development platform, CHOICE, leverages engineered strains of the vaccinia virus to establish an extensive library of product candidates. Its primary clinical candidate, Olvi-Vec, is evaluated across monotherapy and combination settings for patients with aggressive, difficult-to-treat solid tumors who have experienced limited success with conventional standards of care.

The company operates a current Good Manufacturing Practice facility located in San Diego, California, where it manufactures clinical supply and prepares for commercial scale. Genelux also leases an additional building at the San Diego site for research laboratories and administrative functions, while maintaining clinical partnerships in China. Genelux Corporation is headquartered in Westlake Village, California.

Summary of the business section of Genelux's latest annual report, written by StockData.

Company profile

Company

Legal name
GENELUX Corp
Headquarters
Westlake Village, CA
Address
2625 Townsgate Road, Suite 230 91361
Phone
(805) 267-9889
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Weinberg & Company, P.A., Los Angeles, California

Stock & identifiers

Ticker
GNLX
Exchange
Nasdaq
IPO date
Jan 26, 2023
Shares outstanding
45M, Aug 11, 2026
Public float
$89.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1231457
CUSIP
36870H103
ISIN
US36870H1032
FIGI
BBG0044BNBX6
Share class FIGI
BBG0044BNBY5
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Yong YuChief Scientific Officer258,020
Thomas ZindrickPresident and CEO1,423,338
Joseph CappelloChief Technical Officer317,812
Eric GroenGeneral Counsel233,957
Matthew PulisicChief Financial Officer278,906
Ralph SmallingHead of Regulatory67,611
Jason LittenChief Medical Officer–
Sean RyderGeneral Counsel47,621
Lourie S. ZakChief Financial Officer82,452
John W. SmitherDirector91,403
Mary MirabelliDirector102,693
John ThomasDirector501,193
James L. TyreeDirector96,483

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Thomas D. Zindrick
President and Chief Executive Officer
$613.00K$1.42M$2.07M$168.11K$3.05K$4.28M–
Matthew Pulisic
Chief Financial Officer
$406.74K–$997.45K$82.60K$220$1.49M–
Joseph Cappello
Chief Technical Officer
$390.00K$437.63K$533.63K$77.79K$3.05K$1.44M+123%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 26, 2023
Offer price
$6.00
Securities offered
2,500,000
Gross proceeds
$15.00M
Exchange
Nasdaq
First trading day
Jan 26, 2023
First-day close
$6.15+2.5%
Lock-up ends (est.)
Jul 25, 2023

“The initial public offering price is $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?